miR-22 inhibitor

A miR-22 inhibitor is a class of oligonucleotide-based therapeutics, typically antisense oligonucleotides or antagomirs, designed to target and inhibit microRNA-22 (miR-22). miR-22 is a non-coding RNA that plays a key role in regulating metabolic homeostasis, lipid biosynthesis, and fibrogenesis, and is often upregulated in conditions such as obesity, metabolic dysfunction-associated steatohepatitis (MASH), and certain cancers. By silencing miR-22, these inhibitors promote the browning of white adipose tissue, increase energy expenditure, reduce hepatic steatosis, and improve insulin sensitivity. Several candidates, such as RES-010 (Resalis Therapeutics) and APT-110 (AptamiR Therapeutics), are in development for metabolic disorders.

Other names

antago-miR-22antago-miR22antago-miR 22antagomiR-22antagomiR22antagomiR 22anti-miR-22anti-miR22anti-miR 22microRNA-22 inhibitormicroRNA22 inhibitormicroRNA 22 inhibitormiR-22-3p inhibitormiR22-3p inhibitormiR 22-3p inhibitormiR-22-5p inhibitormiR22-5p inhibitormiR 22-5p inhibitor